Search Form
First, enter a politician or zip code
Now, choose a category

Key Votes

HCR 2005 - Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients - Key Vote

Arizona Key Votes

Thomas Forese Co-Sponsored (Introduced) this Legislation.

Read statements Thomas Forese made in this general time period.

Stages

Family

Issues

Stage Details

Legislation - Bill Passed (Senate) (23-6) - (Key vote)

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Vote Smart's Synopsis:

Vote to pass a resolution that submits to the voter a question that authorizes a manufacturer to provide an investigational drug, biological product, or device to eligible patients.

Highlights:
  • Defines “investigational drug, biological product, or device” as a treatment that has successfully completed phase 1 of a clinical trial, but has not been approved for general use by the Food and Drug Administration (Sec. 1).
  • Defines “eligible patient” as an individual who meets certain criteria, including, but not limited to, the following (Sec. 1):
    • The individual has a terminal illness as determined by their physician and a consulting physician;
    • The individual’s physician has determined that there is no satisfactory or comparable Food and Drug Administration approved treatment; and
    • The individual has received a recommendation from their physician for the investigational treatment.
  • Authorizes a manufacturer to require an individual to pay for investigational treatment and to participate in data collection relating to the treatment (Sec. 1).
  • Specifies that a health care insurer or any state agency does not have to provide coverage for the cost of the investigational treatment (Sec. 1).
  • Prohibits any state regulatory board from revoking or failing to renew a physician’s license based on the physician’s recommendation of an investigational treatment (Sec. 1).
  • Specifies that any official, employee, or agent of the state who blocks an eligible patient’s access to an investigational treatment is guilty of a class 1 misdemeanor (Sec. 1).
Legislation - Bill Passed (House) (31-23) - (Key vote)

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Vote Smart's Synopsis:

Vote to pass a resolution that submits to the voter a question that authorizes a manufacturer to provide an investigational drug, biological product, or device to eligible patients.

Highlights:
  • Defines “investigational drug, biological product, or device” as a treatment that has successfully completed phase 1 of a clinical trial, but has not been approved for general use by the Food and Drug Administration (Sec. 1).
  • Defines “eligible patient” as an individual who meets certain criteria, including, but not limited to, the following (Sec. 1):
    • The individual has a terminal illness as determined by their physician and a consulting physician;
    • The individual’s physician has determined that there is no satisfactory or comparable Food and Drug Administration approved treatment; and
    • The individual has received a recommendation from their physician for the investigational treatment.
  • Authorizes a manufacturer to require an individual to pay for investigational treatment and to participate in data collection relating to the treatment (Sec. 1).
  • Specifies that a health care insurer or any state agency does not have to provide coverage for the cost of the investigational treatment (Sec. 1).
  • Prohibits any state regulatory board from revoking or failing to renew a physician’s license based on the physician’s recommendation of an investigational treatment (Sec. 1).
  • Specifies that any official, employee, or agent of the state who blocks an eligible patient’s access to an investigational treatment is guilty of a class 1 misdemeanor (Sec. 1).
Legislation - Introduced (House) -

Title: Authorizes a Manufacturer to Provide Investigational Treatments to Eligible Patients

Sponsors

Co-sponsors

Skip to top
Back to top